Postoperative Adjuvant Treatment in Women with Stage I Endometrial Cancer: A Retrospective Study

Table 1

Patient and tumor characteristics.

Characteristic	A group	B group	C group	D group	-value
N	88	11	66	27
Age (%)					0.2823
<60 y	69 (78.41)	7 (63.64)	55 (83.33)	24 (88.89)
≥60 y	19 (21.59)	4 (36.36)	11 (16.67)	3 (11.11)
Histologic type (%)					0.7971
Adenocarcinoma	81 (92.04)	11 (100)	62 (93.93)	27 (100)
Adenocarcinoma (mesonephric-like)	3 (3.41)	0 (0)	0 (0)	0 (0)
Clear cell carcinoma	1 (1.14)	0 (0)	3 (4.55)	0 (0)
Mucinous papillary (adenocarcinoma of intestinal epithelium)	1 (1.14)	0 (0)	0 (0)	0 (0)
Papillary adenocarcinoma (villous-tubular carcinoma subtype)	0 (0)	0 (0)	1 (1.52)	0 (0)
Serous papillary carcinoma	2 (2.27)	0 (0)	0 (0)	0 (0)
Histologic grade (%)
G1	64 (72.73)	4 (36.36)	26 (39.40)	20 (74.07)
G2	17 (1932)	5 (4545)	30 (4545)	5 (1852)
G3	3 (3.41)	2 (18.18)	8 (12.12)	2 (7.41)
Unknown	4 (4.54)	0 (0)	2 (3.03)	0 (0)
FIGO stage (%)
IA	80 (90.91)	7 (63.64)	49 (74.24)	23 (85.19)
IB	8 (9.09)	4 (36.36)	17 (25.76)	4 (14.81)
Lymphadenectomy
Pelvic lymph node	62 (70.45)	9 (81.82)	54 (81.82)	21 (77.78)	0.9688
Pelviclymph + para-aortic node	12 (12.5)	1 (0.91)	8 (12.12)	1 (3.7)	0.4211
CA125					0.395
<35 U/ml	40 (45.45)	6 (54.55)	35 (53.03)	10 (37.04)
≥35 U/ml	11 (12.50)	2 (18.18)	6 (9.09)	1 (3.70)
Unknown	37 (42.05)	3 (27.27)	25 (37.88)	16 (59.26)
ER (%)					0.0743
+	48 (54.55)	10 (90.91)	49 (74.24)	17 (62.97)
−	8 (9.09)	0 (0)	6 (9.09)	1 (3.70)
Unknown	32 (36.36)	1 (9.09)	11 (16.67)	9 (33.33)
PR (%)
+	41 (46.59)	7 (63.64)	45 (68.18)	18 (66.67)
−	15 (17.05)	3 (27.27)	9 (13.64)	0 (0)
±	0 (0)	0 (0)	1 (1.52)	0 (0)
Unknown	32 (36.36)	1 (9.09)	11 (16.66)	9 (33.33)

A group, no adjuvant treatment; B group: radiotherapy; C group, chemotherapy; D group, MPA + chemotherapy (or) radiotherapy. Abbreviations: FIGO, international federation of gynecology and obstetrics; CA125, carbohydrate antigen-125; ER, estrogen receptor; PR, progesterone receptor. .